Literature DB >> 21910140

International Pig-a gene mutation assay trial: evaluation of transferability across 14 laboratories.

Stephen D Dertinger1, Souk Phonethepswath, Pamela Weller, John Nicolette, Joel Murray, Paul Sonders, Hans-Werner Vohr, Jing Shi, Ljubica Krsmanovic, Carol Gleason, Laura Custer, Andrew Henwood, Kevin Sweder, Leon F Stankowski, Daniel J Roberts, Amanda Giddings, Julia Kenny, Anthony M Lynch, Céline Defrain, Fabrice Nesslany, Bas-jan M van der Leede, Terry Van Doninck, Ann Schuermans, Kentaro Tanaka, Yoshie Hiwata, Osamu Tajima, Eleanor Wilde, Azeddine Elhajouji, William C Gunther, Catherine J Thiffeault, Thomas J Shutsky, Ronald D Fiedler, Takafumi Kimoto, Javed A Bhalli, Robert H Heflich, James T MacGregor.   

Abstract

A collaborative international trial was conducted to evaluate the reproducibility and transferability of an in vivo mutation assay based on the enumeration of CD59-negative rat erythrocytes, a phenotype that is indicative of Pig-a gene mutation. Fourteen laboratories participated in this study, where anti-CD59-PE, SYTO 13 dye, and flow cytometry were used to determine the frequency of CD59-negative erythrocytes (RBC(CD59-)) and CD59-negative reticulocytes (RET(CD59-)). To provide samples with a range of mutant phenotype cell frequencies, male rats were exposed to N-ethyl-N-nitrosourea (ENU) via oral gavage for three consecutive days (Days 1-3). Each laboratory studied 0, 20, and 40 mg ENU/kg/day (n = 5 per group). Three sites also evaluated 4 mg/kg/day. At a minimum, blood samples were collected three times: predosing and on Days 15 and 30. Blood samples were processed according to a standardized sample processing and data acquisition protocol, and three endpoints were measured: %reticulocytes, frequency of RET(CD59-) , and frequency of RBC(CD59-) . The methodology was found to be reproducible, as the analysis of technical replicates resulted in experimental coefficients of variation that approached theoretical values. Good transferability was evident from the similar kinetics and magnitude of the dose-related responses that were observed among different laboratories. Concordance correlation coefficients showed a high level of agreement between the reference site and the test sites (range: 0.87-0.99). Collectively, these data demonstrate that with adequate training of personnel, flow cytometric analysis is capable of reliably enumerating mutant phenotype erythrocytes, thereby providing a robust in vivo mutation assay that is readily transferable across laboratories.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910140     DOI: 10.1002/em.20672

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  12 in total

1.  When pigs fly: immunomagnetic separation facilitates rapid determination of Pig-a mutant frequency by flow cytometric analysis.

Authors:  Stephen D Dertinger; Steven M Bryce; Souk Phonethepswath; Svetlana L Avlasevich
Journal:  Mutat Res       Date:  2011-01-28       Impact factor: 2.433

2.  Comparison of male versus female responses in the Pig-a mutation assay.

Authors:  Carson Labash; Svetlana L Avlasevich; Kristine Carlson; Dorothea K Torous; Ariel Berg; Jeffrey C Bemis; James T MacGregor; Stephen D Dertinger
Journal:  Mutagenesis       Date:  2015-04-01       Impact factor: 3.000

3.  Integration of Pig-a, micronucleus, chromosome aberration and comet assay endpoints in a 28-day rodent toxicity study with urethane.

Authors:  Leon F Stankowski; Marilyn J Aardema; Timothy E Lawlor; Kamala Pant; Shambhu Roy; Yong Xu; Reem Elbekai
Journal:  Mutagenesis       Date:  2015-05-01       Impact factor: 3.000

4.  In vivo pig-a and micronucleus study of the prototypical aneugen vinblastine sulfate.

Authors:  Svetlana L Avlasevich; Carson Labash; Dorothea K Torous; Jeffrey C Bemis; James T MacGregor; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2017-08-19       Impact factor: 3.216

5.  Human erythrocyte PIG-A assay: an easily monitored index of gene mutation requiring low volume blood samples.

Authors:  Stephen D Dertinger; Svetlana L Avlasevich; Jeffrey C Bemis; Yuhchyau Chen; James T MacGregor
Journal:  Environ Mol Mutagen       Date:  2014-11-20       Impact factor: 3.216

6.  Glycosylphosphatidylinositol (GPI) anchored protein deficiency serves as a reliable reporter of Pig-a gene Mutation: Support from an in vitro assay based on L5178Y/Tk+/- cells and the CD90.2 antigen.

Authors:  Jeffrey C Bemis; Svetlana L Avlasevich; Carson Labash; Page McKinzie; Javier Revollo; Vasily N Dobrovolsky; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2017-11-08       Impact factor: 3.216

7.  Sensitivity of the Pig-a assay for detecting gene mutation in rats exposed acutely to strong clastogens.

Authors:  Javed A Bhalli; Joseph G Shaddock; Mason G Pearce; Vasily N Dobrovolsky
Journal:  Mutagenesis       Date:  2013-05-15       Impact factor: 3.000

8.  Efficient monitoring of in vivo pig-a gene mutation and chromosomal damage: summary of 7 published studies and results from 11 new reference compounds.

Authors:  Stephen D Dertinger; Souk Phonethepswath; Svetlana L Avlasevich; Dorothea K Torous; Jared Mereness; Steven M Bryce; Jeffrey C Bemis; Sara Bell; Pamela Weller; James T Macgregor
Journal:  Toxicol Sci       Date:  2012-08-24       Impact factor: 4.849

9.  Single cell gel electrophoresis (SCGE) and Pig-a mutation assay in vivo-tools for genotoxicity testing from a regulatory perspective: a study of benzo[a]pyrene in Ogg1(-/-) mice.

Authors:  Anne Graupner; Christine Instanes; Stephen D Dertinger; Jill Mari Andersen; Birgitte Lindeman; Tonje Danielsen Rongved; Gunnar Brunborg; Ann-Karin Olsen
Journal:  Mutat Res Genet Toxicol Environ Mutagen       Date:  2014-08-07       Impact factor: 2.873

10.  Development of an in vitro PIG-A gene mutation assay in human cells.

Authors:  Benjamin J Rees; Matthew Tate; Anthony M Lynch; Catherine A Thornton; Gareth J Jenkins; Richard M Walmsley; George E Johnson
Journal:  Mutagenesis       Date:  2017-03-01       Impact factor: 2.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.